New Horizon 2020 EURO SHOCK study sets out to improve the outcome for patients with cardiogenic shock
The new EURO SHOCK study is to receive € 5.6 million from the EU, to assess a new procedure of treatment approach for patients suffering cardiogenic shock. The project unites the foremost physicians in cardio-vascular medicine from across Europe, and is determined to become a bench-mark study on one of the few last challenges in this field. The ambition for EURO SHOCK is nothing less than to reduce the mortality associated with cardiogenic shock – a life threatening condition following a severe coronary heart attack.
Cardio-vascular diseases are responsible for more than 4 million deaths across Europe every year. Overall this type of disease is estimated to cost the European economy € 210 billion a year. Acute myocardial infarction, also more commonly known as heart attacks, evolve in about 10% of all cases into cardiogenic shock (in Europe 60.000-70.000 cases per year) with a 50% mortality rate in the first 30 days. This number is even higher in women and elderly patient groups.